Welcome to this webcast on the role and use of targeted therapy with monoclonal antibodies for the treatment of patients with severe uncontrolled asthma. This activity takes a deep dive into asthma phenotypes, including the role of biomarkers, and how this information is used to select biologic therapy. Clinical criteria for assessing treatment response are also discussed.
Want to learn more?
Visit Part 2 to learn more about phenotypes, biomarkers, and how to select monoclonal antibody agents.
1.00 AANP Contact Hour
1.00 AMA PRA Category 1 CreditTM
This activity is intended for allergists, pulmonologists, and other clinicians interested in the management of patients with severe uncontrolled asthma.
This educational activity is supported by an educational grant from GlaxoSmithKline.
Jonathan Corren, MD
Clinical Associate Professor of Medicine and Pediatrics
Division of Clinical Immunology Allergy, Co-Director
UCLA Nasal and Sinus Disease Center
Medical Director, Allergy Research Foundation
Los Angeles, California